{
    "clinical_study": {
        "@rank": "34962", 
        "acronym": "DW224-III-3", 
        "arm_group": [
            {
                "arm_group_label": "DW224", 
                "arm_group_type": "Experimental", 
                "description": "Zabofloxacin Tablet 400mg given by oral administration"
            }, 
            {
                "arm_group_label": "Avelox", 
                "arm_group_type": "Active Comparator", 
                "description": "Moxifloxacin Tablet 400mg given by oral administration"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple\n      dose of Zabofloxacin Tablet 400 mg."
        }, 
        "brief_title": "A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase 3, Multicenter, Double Blind, Active Controlled, Randomized Study to Evaluate the\n      Efficacy and Safety of Zabofloxacin for Patients with acute bacterial exacerbation of\n      Chronic obstructive pulmonary disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male or female same or older than age of 40\n\n          -  Severity of acute exacerbation of COPD must suit oral administration treatment\n\n          -  Diagnosed as COPD before receiving written informed consent and outcome measure of\n             spirometry testing confirmed as FEV1/FVC < 0.7\n\n          -  Subject showing following signs and symptoms:\n\n             (i)Purulent Sputum or Sputum level is increased; (ii)Difficulty in breathing is\n             increased\n\n          -  Female subjects who might be pregnant must do pregnancy test and results should be\n             negative before randomization is done. She must receive written informed consent form\n             (NOTE: Subject who has used single hormone contraception for pregnancy control or has\n             not been more than 1 year after Tubule ligation and menopause are excluded from the\n             study)\n\n          -  Subject who can agree and sign written informed consent form approved by IRB before\n             participating in study and follow study requirements\n\n        Exclusion Criteria:\n\n          -  Subject who administered excess daily dose of antimicrobial/antibiotics in past 72\n             hours before receiving written consent\n\n          -  Diagnosed to have pneumonia by taking chest X-ray in past 48 hours before receiving\n             written consent\n\n          -  Diagnosed to have infectious diseases or such diseases results in complications\n             before receiving written consent (NOTE: Septic shock, Bronchiectasis, Lung abscess,\n             Pneumonia, Active tuberculosis, Pulmonary malignancy, Cystic fibrosis, Empyema,\n             Asthma)\n\n          -  Have kidney or liver diseases who correspond following criteria:\n\n             (i) CCr < 50 mL/min; (ii) BUN \u2265 30 mg/dl; (iii) ALT \ub610\ub294 AST > 3 x ULN; (iv) Total\n             bilirubin > 2 x ULN; (v) ALP > 2 x ULN.\n\n          -  Organic gastrointestinal disorder having abnormal absorption problem condition in\n             past 6 months before receiving written consent (NOTE: Active Crohn's disease, active\n             ulcerative colitis)\n\n          -  Diagnosed to have neutropenia where absolute neutrophil count is < 1,000cells/mm3\n             (NOTE: Even though subject neutrophil count is < 1,000cells/mm3, if it is acute\n             infection, subject maybe possible to participate)\n\n          -  Chronic Hepatitis B carrier\n\n          -  Have proof that subject is Hepatitis C carrier or have Hepatitis C antibody\n\n          -  Immunodeficiency diseases such as HIV positive, AIDS, Bone marrow transplant or\n             leukemia\n\n          -  Have medical history of hypersensitive reaction to antibiotics of fluoroquinolones\n\n          -  Have medical history of seizure or administration of anti-seizure drug in past 1 year\n             before receiving written consent (NOTE: Epilepsy, Convulsions, Myasthenia gravis)\n\n          -  Medical history of ventricular arrhythmia\n\n          -  Medical history of QTc prolongation or currently administering drug that delays QTc\n             interval (NOTE: QTc prolongation means QTc interval > 450 msec)\n\n          -  Complex infections or diseases that can effect study assessment or need long-term\n             antibiotic treatment exceeding 7 days\n\n          -  Subject who has participated in Clinical trials or Bioequivalence test in past 30\n             days before receiving written consent\n\n          -  Clinically significant by observations considered as unsuitable based on medical\n             judgement by investigators where current condition can effect quality of safety or\n             data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "344", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658020", 
            "org_study_id": "DW224-III-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Avelox", 
                "description": "multiple-dose", 
                "intervention_name": "Zabofloxacin Tablet 400mg", 
                "intervention_type": "Drug", 
                "other_name": "DW224"
            }, 
            {
                "arm_group_label": "DW224", 
                "description": "multiple-dose", 
                "intervention_name": "Moxifloxacin Tablet 400mg", 
                "intervention_type": "Drug", 
                "other_name": "Avelox"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Fluoroquinolones", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute exacerbation of Chronic obstructive pulmonary disease", 
            "Acute Exacerbation", 
            "COPD", 
            "Zabofloxacin", 
            "Moxifloxacin", 
            "Avelox", 
            "DW224-III-3", 
            "DW224", 
            "DW224a", 
            "DW224aa"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "link": [
            {
                "description": "Asan Medical Center", 
                "url": "http://medical.amc.seoul.kr/medservice/main/main.do"
            }, 
            {
                "description": "Dong Wha Pharm. Co. Ltd.", 
                "url": "http://www.dong-wha.co.kr/dw_main.asp"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.", 
        "other_outcome": {
            "description": "Safety analysis is done to clinical ITT population and assessed by changes in numbers of results in Adverse Events monitoring, vital signs of populations laboratory examination.", 
            "measure": "Safety Assessment", 
            "safety_issue": "Yes", 
            "time_frame": "36days"
        }, 
        "overall_official": [
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Yeon-Mok Oh, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Sang-Do Lee, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Primary Efficacy", 
            "measure": "Clinical Cure Rate in the clinical populations", 
            "safety_issue": "Yes", 
            "time_frame": "10days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary Efficacy", 
                "measure": "Clinical cure Rate in the clinical population", 
                "safety_issue": "Yes", 
                "time_frame": "36days"
            }, 
            {
                "description": "Secondary Efficacy", 
                "measure": "Clinical cure Rate in the microbiological PP population", 
                "safety_issue": "Yes", 
                "time_frame": "10days"
            }, 
            {
                "description": "Secondary Efficacy", 
                "measure": "Microbiological response rate in the microbiological PP population", 
                "safety_issue": "Yes", 
                "time_frame": "10,36days"
            }, 
            {
                "description": "Secondary Efficacy", 
                "measure": "Change in EXACT-PRO score for clinical populations", 
                "safety_issue": "Yes", 
                "time_frame": "10,36days"
            }, 
            {
                "description": "Secondary Efficacy", 
                "measure": "Change in CAT scores for clinical populations", 
                "safety_issue": "Yes", 
                "time_frame": "10,36days"
            }
        ], 
        "source": "Dong Wha Pharmaceutical Co. Ltd.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chonbuk National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chosun University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bundang CHA Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chungbuk National University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kangdong Sacred Heart Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hanyang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Asan Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gachon University Gil Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Catholic University of Korea", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Konyang University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "KangWon National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gyeongsang National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kyunghee University Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Korea University Anam Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "DongGuk University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Severance Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Yeungnam University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ulsan University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ewha Womans University Mokdong Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Inje University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chonnam National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Catholic University of Korea Saint Paul's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Incheon St.Mary's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Masan Samsung Hospital, South Korea", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Konkuk University Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Keimyung University Dongsan Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wonju Severance Christian Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hallym University Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ajou University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chungnam National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gangneung Asan Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Dong Wha Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}